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ABSTRACT 
Background Cancer-related fatigue can continue long after curative cancer treatment. The aim 
of this study was to investigate sleep and rest-activity cycles in fatigued and non-fatigued cancer 
survivors. We hypothesized that sleep and rest-activity cycles would be more disturbed in 
people experiencing clinically-relevant fatigue, and that objective measures of sleep would be 
associated with the severity of fatigue in cancer survivors. 
Methods: Cancer survivors (n=87) completed a 14-day wrist actigraphy measurement for the 
estimation of sleep and rest-activity cycles. Fatigue was measured using the Functional 
Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F). Participants were 
dichotomised into two groups using a previously validated score (fatigued n=51 and non-
fatigued n=36). Perception of sleep was measured using the Insomnia Severity Index (ISI). 
Results: FACIT-F score was correlated with wake after sleep onset (r =-0.28; p = 0.010), sleep 
efficiency (r=0.26; p=0.016), sleep onset latency (r=-0.31; p=0.044) and ISI score (r=-0.56; p 
<0.001). The relative amplitude of the rest-activity cycles was lower in the fatigued vs. non-
fatigued group (p=0.017; d=0.58).  
Conclusions: After treatment for cancer, the severity of cancer-related fatigue is correlated with 
specific objective measures of sleep, and there is evidence of rest-activity cycle disruption in 
people experiencing clinically-relevant fatigue. 
Keywords: cancer-related fatigue, actigraphy, rest-activity cycle, insomnia  
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INTRODUCTION 
Cancer-related fatigue (CRF) is a common and debilitating symptom experienced by cancer 
survivors 1. It is not relieved by rest or sleep andhas been described as a severe and unrelenting 
feeling of fatigue, or a sustained sense of exhaustion, interfering with usual functioning, and 
therefore it can negatively impact overall quality of life2. CRF can develop during or after 
cancer treatment, and for approximately one-third of people, it can persist for over five years3. 
The potential mechanisms underlying the onset and persistence of CRF are complex and include 
alterations in muscle metabolism, cytokine dysregulation, hypothalamic-pituitary-adrenal axis 
disruption and circadian rhythm dysregulation4,5. Disruption of sleep-wake cycle may 
contribute to CRF, and CRF often co-occurs with chronic sleep disturbance as part of a multi-
symptom cluster6. 
 Patient-reported outcome and several psychometric tools are available for screening and 
assessment of CRF7,8. The Functional Assessment of Chronic Illness Therapy Fatigue Scale 
(FACIT-F;9) is widely used for the assessment of CRF severity with a proposed cut-off point 
for the diagnosis of CRF10. There are no objective measures of CRF, though physiological 
correlates of CRF are under investigation11. The phenomenon is best understood as a subjective 
awareness (described more broadly in neurological illnesses as perception of fatigue)12. 
Although psychometric tools measuring perceptions of sleep exist, objective measures of sleep 
are well established. The gold standard for objective measurement of sleep is laboratory-based 
polysomnography.  
A more practical alternative is wrist actigraphy, which has become a key assessment tool in 
sleep research13. Actigraphy is non-intrusive, can be used to estimate sleep in the participant’s 
habitual sleeping environment, and permits continuous monitoring of both sleep and activity 
over long periods in many participants. Because some cancer survivors experience cognitive 
impairment after cancer treatment a more objective measure of sleep may be desirable14. 
 Poor sleep is commonly reported in cancer survivors6, The overwhelming majority of 
studies measuring sleep during and after cancer treatment use no objective measurement 
techniques15. A robust finding is that there is a discrepancy between subjective and objective 
measures of sleep in people with a sleep disorder16. Many people with insomnia overestimate 
the time taken to fall asleep and underestimate the total amount of sleep relative to objective 
measures16, and such discrepancies have also been reported in cancer survivors17. Many of the 
studies investigating CRF and sleep have only used subjective measures of sleep disruption, 
and a low-moderate correlation has been reported for CRF and subjective sleep quality in 
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survivors of breast cancer18. The relationship with objective measures has received less 
attention, particularly after cancer treatment when CRF may persist indefinitely for some 
people. In one example, increased fatigue with treatment for breast cancer was associated with 
disrupted circadian activity rhythms19, and overall the literature suggests that CRF may be 
related to sleep and rest-activity cycle disturbances20. 
The relationship between perceived fatigue and sleep and rest-activity patterns in cancer 
survivors post-treatment has not been fully elucidated. Therefore, the primary aim of this study 
was to investigate objectively-estimated sleep and rest-activity cycles in fatigued and non-
fatigued cancer survivors. We hypothesized that sleep would be more disturbed in people 
experiencing clinically-relevant CRF, and that objective measures of sleep would be associated 
with the severity of fatigue in cancer survivors. A secondary aim was to investigate the 
mismatch between subjective and objective measures of sleep in a sub-set of our participants. 
 
MATERIAL AND METHODS 
This work was performed at Human Performance Laboratory, Faculty of Kinesiology, 
University of Calgary, Calgary, Canada. 
Participants 
Participants were recruited via the Alberta Cancer Registry (Alberta Health Services, Canada). 
Data extraction criteria included age (≥ 18 and ≤ 75 years), diagnosed with any invasive cancer, 
and postal codes within 20 km of the University of Calgary. From the resulting extraction, equal 
numbers of males and females were randomly sampled and sent a confidential invitation letter 
from the registry (such that the research team did not know who received the invitation, but 
participants could then contact the research team if interested). Participants were also recruited 
via liaising with clinicians and/or advertising at cancer centres local to the University of 
Calgary. Participants were eligible if they had completed initial cancer treatment and were not 
scheduled to receive further treatment during the study period. Initially, 57 participants were 
recruited for the study (REB14-0398: FACIT-F > 34, n = 36; FACIT-F ≤ 34, n = 20). One shift 
worker was not included in the final data analysis. The study was later extended to include an 
exercise program for people with clinically-relevant CRF i.e. FACIT-F ≤ 34, n = 31 
(HREBA.CC-16-10-10, see also Twomey et al.11) meaning that in total, 87 cancer survivors (53 
females) provided written informed consent to participate and completed the study procedures. 
Participant characteristics are presented in Table 1. Approval for all procedures was obtained 
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by the Conjoint Health Research Ethics Board and the Health Research Ethics Board of Alberta 
Cancer Committee (REB14-0398 and HREBA.CC-16-10-10, respectively). 
 
Study Design 
Participants attended two lab visits. On the initial lab visit, participants completed a health 
screening and a number of other procedures as part of a wider project investigating cancer-
related fatigue. Participants were provided with an actigraphy system and sleep diary (see later 
sections) and the data collection period was two weeks. After the data collection period, 
participants attended the lab to return the MotionWatch 8© and sleep diary. On this lab visit, 
participants completed the FACIT-F scale and the Insomnia Severity Index (ISI)21. 
 
Actigraphy 
The MotionWatch 8© actigraphy system (CamNtech Ltd, UK) is an unobtrusive, waterproof, 
wrist-worn device containing a light sensor and a tri-axial accelerometer detecting acceleration 
in a 0.01-8 g range. The device recorded 30-s epochs (as per manufacturer guidelines), and light 
intensity. The device was worn on the non-dominant wrist for a continuous two-week period to 
obtain aggregated measures that characterize individuals and quantify sleep in accordance with 
established recommendations13,22. 
 
Sleep Diary 
Participants were also provided with a sleep diary to complete alongside the actigraphy 
measurement23 to assist with editing the actigraph data for better accuracy24. Information 
provided by the participants (self-report) included “lights out” time (i.e., 8:30 PM), estimated 
sleep onset (time) and night-time awakenings (number/night). 
 
Cancer-Related Fatigue 
The FACT-F is a 13-item, 5-point Likert scale. The scale has a cut off to distinguish fatigued 
patients from non-fatigued patients, with scores ≤ 34 indicating clinically relevant fatigue10. 
The scale has high internal consistency 9 and is widely used in the literature25.  
 
Insomnia Severity 
Perceived severity of insomnia over the previous two weeks was measured using the ISI21. 
Questions address difficulty falling asleep, maintaining sleep and the frequency of early 
morning awakenings, as well as the degree of dissatisfaction with current sleep. The ISI has 
6 
 
been validated in cancer survivors26. Items are rated from 0 (none) to 4 (very severe), scores 
range from 0-28 (≥ 8 indicates clinical insomnia) and gives maximal sensitivity and specificity 
for the detection of sleep difficulties27. The ISI was a late addition to the protocol and therefore 
only 66 participants completed this questionnaire. 
 
Data Analysis 
Estimated sleep characteristics were derived from actigraphy. Actigraph data were analyzed 
with Motionware® version 1.1.20 software (CamNtech Ltd, UK). As recommended in the 
literature28, actigraph data were edited to correspond with the completed sleep diary. In cases 
when the actigraph data and sleep diary disagreed on the initiation of sleep, the light sensor data 
was used to determine the approximate “lights out” time, or when the participant first tried 
falling asleep. Similarly, the light data and the first large increase in activity onset were used to 
determine the end of the sleep window when the actigraph data and sleep diary did not 
correspond. This type of data editing has been performed in a previous study of older adults24. 
Sleep variables estimated by Motionware® included total sleep time (TST: time spent asleep at 
night), sleep efficiency (SE: percentage of time spent sleeping in relation to time spent in bed), 
sleep onset latency (SOL: amount of time taken to fall asleep), wake after sleep onset (WASO: 
min awake after an extended period of sleep), and fragmentation index (FI: indication of sleep 
quality based on the sum of the ‘Mobile time (%)’ and the ‘Immobile bouts ≤ 1min (%) 
calculated by the software). A high sensitivity setting was used, with a time awake threshold of 
20 counts per epoch, and sleep onset was defined as the first period with a minimum of 10 min 
of consecutively recorded immobile data with no more than 1 epoch of movement within that 
time (as validated by the manufacturer). 
 The characteristics of the rest-activity cycle were analyzed with the Non-Parametric 
Circadian Rhythm Analysis (NPCRA) function. We considered the following parameters to 
characterize the rest-activity cycle: estimated peak time of activity (the time of day when the 
peak of the cosine function fitted to the average 24 h data occurs), relative amplitude of the rest-
activity cycle (the difference between the mean activity in the estimated least and most active 
periods, with theoretical range of 0 to 1, where higher values indicate a rhythm with higher 
amplitude)29. The following parameters were also estimated from the raw MotionWatch® 8 
data: mean activity for wake and sleep periods (the mean amount of movement while out of 
bed, and the mean amount of movement while in bed, respectively) and index of activity for 
wake and sleep, calculated as the percentage of activity > 0 per epoch for wake and sleep periods 
respectively30,31. 
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Statistical Methods 
An a priori sample size estimation was performed using G*Power 3 (v3.1.2-3.1.9)32 for the 
relationship between FACIT-F and objectively-estimated sleep parameters. For a correlation 
coefficient of r = 0.3 (i.e. a small effect), with α = 0.05 and a 1-β = 0.80, the sample size required 
was calculated as 85. All data were analyzed using IBM SPSS version 23 statistical software 
(IBM Corporation, Chicago, IL). Data were checked for normality using the Skewness-Kurtosis 
test combined with visual inspection of histograms and Q-Q plots. Data were also checked for 
homogeneity of variance using Levene’s test. To test the hypothesis that participants 
experiencing clinically-relevant fatigue would have poorer sleep than those who were not, 
participants were dichotomised into two groups using FACIT-F > 34 and ≤ 34 (labelled non-
fatigued and fatigued, respectively) and parameters relating to sleep and the rest-activity cycle 
were compared using independent samples t-tests, or non-parametric Mann-Whitney tests when 
data were not normally distributed. Significant results were controlled multiple comparisons 
using the Benjamini & Hochberg false discovery rate procedure33,34. This procedure compares 
each individual p value to its Benjamini-Hochberg critical value, (i/m)Q, where i is the rank, m 
is the total number of comparisons, and Q is the chosen false discovery rate (FDR). FDR Q 
values usually range from 0.05 (relatively conservative) to 0.2 (liberal). Due to the exploratory 
nature of this study, that participants daily living cannot be controlled, the limitations of using 
actigraphy despite its demonstrated validity and reliability13, and the importance of not missing 
a potentially meaningful difference, we chose an intermediate FDR of Q = 0.1. Effect sizes for 
pairwise comparisons were calculated as Cohen’s d35,36. Interpretation of the size of the effect 
was considered as d = 0.2 is small, d = 0.5 is medium and d = 0.8 is large35. The relationships 
between FACIT-F score and sleep and rest-activity outcomes were examined using Pearson 
correlation coefficients or Spearman correlation coefficients, as appropriate. The relationship 
between perceptions of sleep (ISI score) and sleep outcomes were also examined using Pearson 
correlation coefficients or Spearman correlation coefficients. The threshold for statistical 
significance of Pearson and Spearman correlations coefficients was set at p < 0.05. 
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RESULTS 
Of the 87 participants, 51 cancer survivors had CRF (fatigued group) and 36 cancer survivors 
were non-fatigued according to FACIT-F scores. Participant characteristics and FACIT-F 
scores are presented in Table 1. Time since treatment was not correlated with FACIT-F scores 
(r = 0.136; p = 0.283). Many of the participants were highly educated (49%), white (89%), 
female (61%), and survivors of breast cancer (44%). 
 
Objective Measures of Sleep 
In the fatigued group, participants had greater WASO (p = 0.046, d = 0.43) and SOL (p = 0.053, 
d = 0.35) using the Benjamini-Hochberg procedure. No other significant differences between 
groups were observed (Table 2). Overall, participants took 15 ± 13 min to fall asleep at night, 
were asleep for 421 ± 45 min per night (7.0 ± 0.8 h), spent 58 ± 20 min awake after initially 
falling asleep, had a mean SE of 84.6 ± 5.0% and a FI of 28.7 ± 9.2. FACIT-F score was 
correlated with wake after sleep onset (r = -0.28; p = 0.010), sleep efficiency (r = 0.26; p = 
0.016), and sleep onset latency (ρ = -0.31; p = 0.004). FACIT-F score was not correlated with 
total sleep time (r = 0.04; p = 0.696) or fragmentation index (r = -0.16; p = 0.130). Correlations 
are presented in Figure 1A-E. 
 
Rest-Activity Cycles 
The amount of movement during the sleep period (mean sleep actigraphy and index of activity 
during sleep) were both higher in the fatigued vs. the non-fatigued group (Table 2). The relative 
amplitude of the rest-activity cycle was lower in fatigued vs. the non-fatigued group (p = 0.007, 
d = 0.62) using the Benjamini-Hochberg procedure. Peak time of the rest-activity cycle 
occurred ~ 40 min later in the fatigued than in the non-fatigued group (p = 0.007, (d = 0.62). 
The fatigued group also went to bed 25 min later (p = 0.03, d = 0.48) and woke up 40 min later 
(p = 0.009, d = 0.58) than non-fatigued participants. The index of activity during wake period 
(mean wake actigraphy) was not different between groups. FACIT-F score was negatively 
correlated with the peak time of the rest-activity cycle (r = -0.32; p = 0.002), bed time (r = -
0.26; p = 0.014), and wake-up time (r = -0.28; p = 0.008).  FACIT-F score was also correlated 
with amount of movement during the sleep period (i.e. the index of activity during sleep: r = -
0.39; p < 0.001), mean sleep actigraphy (ρ = -0.39; p < 0.001), relative amplitude (ρ = 0.31; p 
= 0.003). FACIT-F was not correlated with other rest-activity cycle parameters (Supplemental 
Table 1). 
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Perception of Sleep Disruption 
The mean ISI score was significantly higher in the fatigued vs. non-fatigued group (Table 2). 
In the fatigued group, the vast majority of participants (83%, n = 35) reported clinically-relevant 
sleep disruption (ISI total score > 827). Of these 35 participants, 20 reported subthreshold 
insomnia (ISI total score 8-14), 12 reported moderate severity insomnia (ISI total score 15-21), 
and 3 reported severe insomnia (ISI total score 22-28). In the non-fatigued group, half of 
participants (50%, n = 12) reported clinically-relevant sleep disruption (ISI total score > 827). 
Of these 12 participants, 10 reported subthreshold insomnia (ISI total score 8-14) and 2 reported 
moderate severity insomnia (ISI total score 15-21). 
The relationship between perceived sleep and perceived fatigue is presented in Figure 
1F. The ISI total score was negatively and significantly associated with FACIT-F score (r = -
0.56; p < 0.001). That is, more severe perceived difficulties with sleep were associated with 
more severe ratings of fatigue. We also examined relationships between total ISI score and 
actigraphy-estimated sleep outcomes. Total ISI score was not correlated with TST (r = -0.076; 
p = 0.546), WASO (r = 0.24; p = 0.051), or FI (r = 0.06; p = 0.608). However, the total ISI 
score was significantly correlated with SE (r = -0.34; p = 0.006), and sleep onset latency (ρ = 
0.30; p = 0.013) (Supplemental Table 2). 
 
DISCUSSION 
The primary aim of this study was to investigate objectively-estimated sleep and rest-activity 
cycles in fatigued and non-fatigued cancer survivors. In line with our hypothesis, some 
actigraphy-derived markers of sleep were associated with the severity of fatigue in cancer 
survivors, including parameters associated with more awakening and movement during the 
sleep period. To our knowledge, this is the first study to investigate sleep and rest-activity cycle 
disruption months and years after cancer treatment comparing fatigued and non-fatigued cancer 
survivors. A secondary aim of this study was to investigate the association between subjective 
and objective measures of sleep in a sub-set of our participants. We found that people with CRF 
perceived their sleep as worse than non-fatigued survivors, and this perception was associated 
with both fatigue severity and several, although not all, objective sleep parameters. 
 
The relationship between fatigue and actigraphy-derived sleep and comparison to 
Reference Data for Sleep Duration and Quality 
CRF is a complex issue that for some people can continue for years after cancer treatment. CRF 
and poor sleep can occur simultaneously, but the relationship between CRF and actigraphy-
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derived estimates of sleep has not been investigated after cancer treatment. The current findings 
show a small but significant association between fatigue assessed with FACIT-F and specific 
objective parameters, including wake after sleep onset, sleep efficiency and sleep onset latency. 
In cancer survivors, difficulties initiating sleep and the robustness/quality of the sleep episode 
may contribute to the perception of CRF which persists after treatment completion. This is a 
major concern for health-related quality of life and societal issues, including return to work and 
productivity at work37. Interestingly, there was no relationship between CRF and total sleep 
time. Existing research shows that the time devoted to sleep is similar for cancer patients and 
healthy controls38. Moreover, total sleep time has been shown to be similar at across various 
points during cancer treatment, and similar to a healthy population up to one year after 
treatment39. 
Using dichotomized groups based on a pre-specified and validated cut off point10, we found 
that participants categorized as fatigued vs. non-fatigued had a marginally greater time spent 
awake after sleep onset and time to fall asleep. The current study did not include a control 
group, but recent data from the National Sleep Foundation may be used as reference data for 
sleep duration and quality. We identified 38 people (44%) who slept less than the 
recommendation for sleep duration40. These participants were approximately evenly distributed 
across dichotomised groups (43% of fatigued and 44% of non-fatigued, respectively). 
Concerning other sleep parameters, a good sleep quality was defined as WASO < 51 min, SOL 
< 30 min or SE > 85%41. Specifically, only 37% of fatigued people were awake at night for < 
51 min, versus 50% in the non-fatigued group. There was also a small and small-medium effect 
for sleep efficiency and sleep onset latency, respectively. Poor quality sleep in cancer survivors 
has been mainly associated with high wake time at night and a long sleep onset latency, rather 
than less total nocturnal sleep time42. The fact that approximately double the number of 
participants had issues with sleep efficiency and latency in the fatigued vs. non-fatigued group 
suggests that difficulties with beginning/maintaining sleep (like in insomnia) relate to 
subjective feelings of fatigue. Specifically, for latency, 16% of the fatigued group took longer 
than 30 min to fall asleep (8% in the non-fatigued group) and 59% had a sleep efficiency less 
than 85% (versus 33% in the non-fatigued group). A low sleep efficiency is a major concern, 
given that a less efficient sleep has been associated with lower survival in people living with 
and beyond cancer43. In summary, more severe fatigue seems to be related to more difficulties 
to achieve a good sleep. Even though precise mechanisms are unknown, both CRF and sleep 
disorders share a common symptom cluster including modification of immune function, 
dysregulation of hypothalamic-pituitary axis and circadian rhythms, pain, and depression, that 
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may be the basis of a reciprocal relationship between sleep disorders and CRF5,6. Further 
investigation is required since cancer survivors in the present study had completed initial cancer 
treatment only (e.g. surgery, chemotherapy and/or radiation therapy). Some long-term adjuvant 
treatments, specifically hormonal therapy, may affect daytime activity and sleep quality44.  
 
The relationship between fatigue and rest-activity cycles in cancer survivors 
Sleep has a reciprocal relationship with circadian rhythm disturbances in that sleep disruption 
might adversely affect circadian function, and disrupted circadian function can contribute to the 
development of sleep disorders43. The estimated cosine peak time of the rest-activity cycle 
occurred later in fatigued than in non-fatigued survivors in our study, which was correlated with 
CRF scores. Fatigued survivors also had delayed bed and wake up times. Phase delays of the 
rest-activity cycle have been previously observed in patients with depressive symptoms 
presenting low sleep quality45. More importantly, despite similar indices of daytime activity, 
fatigued survivors exhibited more body movement during sleep and a lower relative amplitude 
of the rest-activity cycle cosine estimation. Both were also associated with CRF. Lower 
amplitude of the rest-activity cycle has previously been observed after treatment in cancer 
survivors compared to control participants19. Previous results in cancer survivors have 
highlighted a clear dichotomy between day-time and night-time actigraphy, with high activity 
during wake time and low activity during night time, being associated with better quality of 
life46.  Interestingly, Ancoli-Israel et al.39 observed that characteristics of the rest-activity cycle 
returned to baseline one year after treatment, despite being lower than healthy controls. 
Although no comparison to a control population was included in the current study, our results 
show that fatigued participants have a lower amplitude of the rest-activity cycle than non-
fatigued participant months and years after treatment. An altered rest-activity cycle may also 
be related to other symptoms associated with cancer such as pain and depression6. Further 
experiments in people with clinically-relevant CRF are needed to better understand the link 
between circadian rhythms disruption and persistent CRF after treatment.  
 
The mismatch between subjective and objective measures of sleep 
Subjective sleep does not always correspond with actigraph data due to the presence of other 
symptoms or psychological and physiological factors38. However, fatigue is one of the most 
reported complaints of patients with insomnia47. The longer time spent awake during the night 
and the longer time taken to fall asleep observed in fatigued participants, corroborates the higher 
subjective feeling of insomnia in this study. As a self-report, the ISI was chosen since insomnia 
12 
 
is common in cancer survivors reporting having sleep disorders48. We found that the majority 
(83%) of fatigued participants in the present study reported significant sleep disruption (ISI 
total score > 8), whereas this was reduced to 50% in the non-fatigued group. Dirksen et al.49 
showed that cancer survivors with the highest level of fatigue reported higher scores on the ISI, 
which was in accordance with the present study, suggesting that CRF may be linked to the 
perception of sleep disturbance in cancer populations. ISI scores in our study were lower (less 
self-reported insomnia) than in previous studies in cancer survivors where ISI was used to 
assess insomnia after treatment50, however these studies focused on cancer survivors with 
clinical insomnia.  
Based on the results of the present study, interventions for CRF after cancer treatment 
should target both the perception of sleep and the improvement of objectively-measured sleep. 
Two interventions which may have promise for treating sleep disturbance are exercise20 and 
cognitive behavioral therapy51. 
 
Limitations 
There are several limitations of the current study. As previously highlighted, these results are 
based on a sample of predominantly white, female, survivors of breast cancer and therefore may 
not be representative of a more diverse population or generalizable to specific tumour groups. 
Dichotomization of the FACIT-F score, although using a validated cut-off 10 may have resulted 
in misclassification of some individuals. We did not ask participants about the perception of 
their sleep quality and quantity prior to their cancer diagnosis because the recall period would 
have been > 12 months for most. Therefore, it was not possible to comment on whether sleep 
and rest-activity cycle disruption was cancer-related. Future longitudinal studies should aim to 
investigate the relationship between fatigue and sleep during the period between diagnosis and 
treatment, and at time-points encompassing treatment and recovery. Actigraphy has some key 
limitations that have been discussed previously13, such as the underestimation of SOL and 
overestimation of SE. It cannot be considered as a substitute for clinical interviews or overnight 
polysomnography and information about the modification of sleep architecture between people 
with and without CRF must also be measured in future studies. There is also a risk of bias due 
to lack of compliancy in participants completing the sleep diary (which was used to edit the 
actigraph data to improve accuracy). The limitation of paper diaries is that aspects of 
compliance (such as the recall period) cannot be monitored by the experimenter in real time, 
and participants may not remember to complete the diary every day52. However, this limitation 
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was minimized by using the light sensor data to indicate sleep and wake onset when the sleep 
diary and actigraph data were otherwise incongruent52.  
 
Conclusion 
This is the first study to show that after treatment for cancer, the severity of CRF is correlated 
with specific objective measures of sleep including sleep onset latency, wake time at night and 
sleep efficiency, but not total sleep duration. The subjective perception of difficulties with sleep 
was worse in people with clinically-relevant CRF. In addition, the severity of CRF is correlated 
to the amount of movement during the sleep period, and we observed evidence of disrupted 
rest-activity cycles in people experiencing CRF. Future studies should focus on the potential 
benefits of interventions that influence both objective and subjective measure of sleep in people 
with CRF after cancer treatment, particularly exercise. These findings have direct consequences 
on the rehabilitation process, even months and years after cancer treatment. 
  
14 
 
CONFLICT OF INTEREST 
No competing interests 
ACKNOWLEDGEMENTS 
Authors sincerely acknowledge all participants for their involvement in this study.  
This research is funded by the Canadian Cancer Society (grant #704208-1). Canadian cancer 
society has no a role in study design, collection, analysis and interpretation of data; in the 
writing of the report; and in the decision to submit the article for publication. 
  
15 
 
References 
1  Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancer-related fatigue: A critical appraisal. 
Eur J Cancer 2006; 42: 846–863. 
2  Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D et al. 
Cancer-Related Fatigue, Version 2.2015. J Natl Compr Cancer Netw 2015; 13: 1012–
1039. 
3  Jones JM, Olson K, Catton P et al. Cancer-related fatigue and associated disability in 
post-treatment cancer survivors. J Cancer Surviv Res Pract 2016; 10: 51–61. 
4  O’Higgins CM, Brady B, O’Connor B, Walsh D, Reilly RB. The pathophysiology of 
cancer-related fatigue: current controversies. Support Care Cancer Off J Multinatl Assoc 
Support Care Cancer 2018; 26: 3353–3364. 
5  Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR. Mechanisms of 
cancer-related fatigue. The Oncologist 2007; 12 Suppl 1: 22–34. 
6  Roscoe JA, Kaufman ME, Matteson-Rusby SE, Palesh OG, Ryan JL, Kohli S et al. 
Cancer-related fatigue and sleep disorders. The Oncologist 2007; 12: 35–42. 
7  Howell D, Keshavarz H, Broadfield L, Hack T, Hamel M, Harth T, J et al., on behalf of 
the Cancer Journey Advisory Group of the Canadian Partnership Against Cancer. A Pan 
Canadian Practice Guideline for Screening, Assessment, and Management of Cancer-
Related Fatigue in Adults Version 2-2015, Toronto: Canadian Partnership Against Cancer 
(Cancer Journey Advisory Group) and the Canadian Association of Psychosocial 
Oncology, April 2015. DOI: https://doi.org/10.7939/R33R6N. 
8  Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-
related fatigue (CRF). Ann Oncol 2008; 20: 17–25. 
9  Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other 
anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) 
measurement system. J Pain Symptom Manage 1997; 13: 63–74. 
10  Van Belle S, Paridaens R, Evers G et al. Comparison of proposed diagnostic criteria with 
FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool. Support 
Care Cancer Off J Multinatl Assoc Support Care Cancer 2005; 13: 246–254. 
11  Twomey R, Martin T, Temesi J, Culos-Reed SN, Millet GY. Tailored exercise 
interventions to reduce fatigue in cancer survivors: study protocol of a randomized 
controlled trial. BMC Cancer 2018; 18: 757. 
12  Kluger BM, Krupp LB, Enoka RM. Fatigue and fatigability in neurologic illnesses: 
proposal for a unified taxonomy. Neurology 2013; 80: 409–416. 
13  Sadeh A. The role and validity of actigraphy in sleep medicine: an update. Sleep Med Rev 
2011; 15: 259–267. 
14  Pendergrass JC, Targum SD, Harrison JE. Cognitive Impairment Associated with Cancer. 
Innov Clin Neurosci 2018; 15: 36–44. 
16 
 
15  Otte JL, Carpenter JS, Manchanda S et al. Systematic review of sleep disorders in cancer 
patients: can the prevalence of sleep disorders be ascertained? Cancer Med 2015; 4: 183–
200. 
16  Harvey AG, Tang N. (Mis)Perception of Sleep in Insomnia: A puzzle and a resolution. 
Psychol Bull 2012; 138: 77–101. 
17  Reinsel RA, Starr TD, O’Sullivan B, Passik SD, Kavey NB. Polysomnographic Study of 
Sleep in Survivors of Breast Cancer. J Clin Sleep Med JCSM Off Publ Am Acad Sleep 
Med 2015; 11: 1361–1370. 
18  Banthia R, Malcarne VL, Ko CM, Varni JW, Sadler GR. Fatigued Breast Cancer 
Survivors: The Role of Sleep Quality, Depressed Mood, Stage, and Age. Psychol Health 
2009; 24: 965–980. 
19  Liu L, Rissling M, Neikrug A et al. Fatigue and Circadian Activity Rhythms in Breast 
Cancer Patients Before and After Chemotherapy: A Controlled Study. Fatigue Abingdon 
Eng Print 2013; 1: 12–26. 
20  Medysky ME, Temesi J, Culos-Reed SN, Millet GY. Exercise, sleep and cancer-related 
fatigue: Are they related? Neurophysiol Clin Clin Neurophysiol 2017; 47: 111–122. 
21  Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an 
outcome measure for insomnia research. Sleep Med 2001; 2: 297–307. 
22  van Someren EJ. Improving actigraphic sleep estimates in insomnia and dementia: how 
many nights? J Sleep Res 2007; 16: 269–275. 
23  Morgenthaler TI, Lee-Chiong T, Alessi C et al. Practice parameters for the clinical 
evaluation and treatment of circadian rhythm sleep disorders. An American Academy of 
Sleep Medicine report. Sleep 2007; 30: 1445–1459. 
24  Landry GJ, Best JR, Liu-Ambrose T. Measuring sleep quality in older adults: a 
comparison using subjective and objective methods. Front Aging Neurosci 2015; 7. 
doi:10.3389/fnagi.2015.00166. 
25  Andersen C, Rørth M, Ejlertsen B et al. The effects of a six-week supervised multimodal 
exercise intervention during chemotherapy on cancer-related fatigue. Eur J Oncol Nurs 
Off J Eur Oncol Nurs Soc 2013; 17: 331–339. 
26  Savard M-H, Savard J, Simard S, Ivers H. Empirical validation of the Insomnia Severity 
Index in cancer patients. Psychooncology 2005; 14: 429–441. 
27  Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: 
Psychometric Indicators to Detect Insomnia Cases and Evaluate Treatment Response. 
Sleep 2011; 34: 601–608. 
28  Lockley SW, Skene DJ, Arendt J. Comparison between subjective and actigraphic 
measurement of sleep and sleep rhythms. J Sleep Res 1999; 8: 175–183. 
17 
 
29  Bonmati-Carrion MA, Middleton B, Revell VL, Skene DJ, Rol MA, Madrid JA. 
Validation of an innovative method, based on tilt sensing, for the assessment of activity 
and body position. Chronobiol Int 2015; 32: 701–710. 
30  Afonso P, Brissos S, Figueira ML, Paiva T. Schizophrenia patients with predominantly 
positive symptoms have more disturbed sleep–wake cycles measured by actigraphy. 
Psychiatry Res 2011; 189: 62–66. 
31  Martin T, Moussay S, Bulla I et al. Exploration of Circadian Rhythms in Patients with 
Bilateral Vestibular Loss. PloS One 2016; 11: e0155067. 
32  Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a flexible statistical power 
analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 
2007; 39: 175–191. 
33  Benjamini Y, Hochberg Y. Controlling The False Discovery Rate - A Practical And 
Powerful Approach To Multiple Testing. J R Stat Soc Ser B 1995; 57: 289–300. 
34  Lee S, Lee DK. What is the proper way to apply the multiple comparison test? Korean J 
Anesthesiol 2018; 71: 353–360. 
35  Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale: 
Lawrence Erlbaum, 1998. 
36  Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a 
practical primer for t-tests and ANOVAs. Front Psychol 2013; 4: 863. 
37  Islam T, Dahlui M, Majid H et al. Factors associated with return to work of breast cancer 
survivors: a systematic review. BMC Public Health 2014; 14: S8. 
38  Berger AM. Update on the state of the science: sleep-wake disturbances in adult patients 
with cancer. Oncol Nurs Forum 2009; 36: E165-177. 
39  Ancoli-Israel S, Liu L, Rissling M et al. Sleep, fatigue, depression, and circadian activity 
rhythms in women with breast cancer before and after treatment: a 1-year longitudinal 
study. Support Care Cancer 2014; 22: 2535–2545. 
40  Hirshkowitz M, Whiton K, Albert SM et al. National Sleep Foundation’s sleep time 
duration recommendations: methodology and results summary. Sleep Health J Natl Sleep 
Found 2015; 1: 40–43. 
41  Ohayon M, Wickwire EM, Hirshkowitz M et al. National Sleep Foundation’s sleep 
quality recommendations: first report. Sleep Health 2017; 3: 6–19. 
42  Natale V, Innominato PF, Boreggiani M et al. The difference between in bed and out of 
bed activity as a behavioral marker of cancer patients: A comparative actigraphic study. 
Chronobiol Int 2015; 32: 925–933. 
43  Palesh O, Aldridge-Gerry A, Zeitzer JM et al. Actigraphy-Measured Sleep Disruption as a 
Predictor of Survival among Women with Advanced Breast Cancer. Sleep 2014; 37: 837–
842. 
18 
 
44  Costa AR, Fontes F, Pereira S, Gonçalves M, Azevedo A, Lunet N. Impact of breast 
cancer treatments on sleep disturbances – A systematic review. The Breast 2014; 23: 697–
709. 
45  Winkler D, Pjrek E, Praschak-Rieder N et al. Actigraphy in Patients with Seasonal 
Affective Disorder and Healthy Control Subjects Treated with Light Therapy. Biol 
Psychiatry 2005; 58: 331–336. 
46  Mormont M-C, Waterhouse J, Bleuzen P et al. Marked 24-h rest/activity rhythms are 
associated with better quality of life, better response, and longer survival in patients with 
metastatic colorectal cancer and good performance status. Clin Cancer Res 2000; 6: 
3038–3045. 
47  Davis MP, Khoshknabi D, Walsh D, Lagman R, Platt A. Insomnia in patients with 
advanced cancer. Am J Hosp Palliat Care 2014; 31: 365–373. 
48  Fleming L, Randell K, Stewart E, Espie CA, Morrison DS, Lawless C et al. Insomnia in 
breast cancer: a prospective observational study. Sleep 2018. doi:10.1093/sleep/zsy245. 
49  Dirksen SR, Belyea MJ, Epstein DR. Fatigue-Based Subgroups of Breast Cancer 
Survivors With Insomnia: Cancer Nurs 2009; 32: 404–411. 
50  Ritterband LM, Bailey ET, Thorndike FP, Lord HR, Farrell-Carnahan L, Baum LD. 
Initial evaluation of an Internet intervention to improve the sleep of cancer survivors with 
insomnia. Psychooncology 2012; 21: 695–705. 
51  Matthews E, Carter P, Page M, Dean G, Berger A. Sleep-Wake Disturbance: A 
Systematic Review of Evidence-Based Interventions for Management in Patients With 
Cancer. Clin J Oncol Nurs 2018; 22: 37–52. 
52  Jungquist CR, Pender JJ, Klingman KJ, Mund J. Validation of Capturing Sleep Diary 
Data via a Wrist-Worn Device. Sleep Disord 2015; 2015: 758937. 
 
 
  
19 
 
Table I Participant Characteristics 
   
    All Fatigued 
Non-
Fatigued  
N   87 51 36 
Age (years)  55.8 ± 10.2 54.2 ± 8.9 58.2 ± 11.6 
Months Since Treatment  33.4 ± 28.7 40.1 ± 28.9 29.9 ± 27.1 
Sex Female 53 [61] 32 [63] 21 [58] 
 Male 34 [39] 19 [37] 15 [42] 
Ethnicity (self-identified)a White 76 [89] 43 [88] 33 [98] 
 Middle Eastern 1 [1] 0 [0] 1 [3] 
 Asian 5 [6] 4 [8] 1 [3] 
 Black 1 [1] 1 [2] 0 [0] 
 First Nations 2 [2] 1 [2] 1 [3] 
Marital Status a Married/Common Law 64 [75] 34 [69] 30 [83] 
 Divorced 12 [14] 6 [12] 6 [17] 
 Single 7 [8] 7 [14] 0 [0] 
 Widowed 2 [2] 2 [4] 0 [0] 
Education a University 42 [49] 25 [51] 17 [48] 
 College 26 [31] 16 [33] 10 [28] 
 Secondary School 14 [17] 5 [10] 9 [25] 
 Other 3 [4] 3 [6] 0 [0] 
Employment Status Part-Time 14 [17] 6 [12] 8 [22] 
 Full-Time 34 [40] 23 [47] 11 [31] 
 Retired 20 [24] 6 [12] 14 [39] 
 Unemployed 7 [8] 5 [10] 2 [6] 
 Disability/Leave 10 [12] 9 [18] 1 [3] 
Cancer Type Breast 38 [44] 22 [43] 16 [44] 
 Prostate 15 [17] 4 [8] 11 [31] 
 Head & Neck 8 [9] 6 [12] 2 [6] 
 Colorectal 7 [8] 5 [10] 2 [6] 
 Hematologic 1 [1] 1 [2] 0 [0] 
 Other 18 [21] 13 [26] 5 [14] 
FACIT-F Score  33 ± 10 26 ± 6 43 ± 6 
aDemographic data about ethnicity, marital status and education were not provided for two fatigued participants. 
Data are presented as mean ± SD for continuous data or count [percentage] for categorical data. Some 
values may not sum to 100% due to rounding. Other cancer types included bladder, testicular, 
endometrial, lymphoma, kidney, lymphoma, papillary, esophageal, thyroid, seminoma, 
choriocarcinoma, pancreatic, brain, cervical 
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Table II Sleep and Rest-Activity Cycle Parameters for Fatigued and Non-Fatigued Cancer 
survivors. 
  Fatigued (n=51) Non-Fatigued (n=36)   
Outcome Mean SD Mean SD p [q] Effect Size 
Sleep (Actigraphy)       
Total Sleep Time (min) 422.6 44.9 417.9 46.3 0.632 [0.100] 0.10 
Sleep Efficiency (%) 84.1 4.7 85.3 5.3 0.285 [0.071] 0.23 
Sleep Onset Latency (min)np 17.3 13.1 12.9 11.9 0.053a [0.064] 0.35 
Wake After Sleep Onset (min) 61.2 22.4 52.9 15.7 0.046a [0.057] 0.43 
Fragmentation Index 29.5 9.4 27.5 8.9 0.305 [0.086] 0.23 
Perceptions of Sleep       
Insomnia Severity Index 12.7 5.6 8.0 5.6 0.020 a [0.043] 0.84 
Rest-Activity Cycle       
Relative amplitude np 0.88 0.07 0.91 0.05 0.017a [0.029] 0.58 
Bed times 23h21 0h57 22h55 00h48 0.033a [0.05] 0.48 
Wake up times 7h40 01h07 6h59 01h11 0.009a [0.021] 0.58 
Peak Time (hh:mm)  14h40 01h14 14h00 00h53 0.007a [0.007] 0.62 
Mean Sleep Actigraphy (MW8 counts) np 15.6 6.9 12.8 6.5 0.018a [0.036] 0.42 
Mean Wake Actigraphy (MW8 counts)  101.3 33.6 109.6 37.0 0.289 [0.079] 0.23 
Index of Activity during Wake (%) 68.9 9.3 70.8 10.0 0.364 [0.093] 0.20 
Index of Activity during Sleep (%) 14.3 3.8 12.8 3.7 0.008* [0.014] 0.60 
a indicates p values which are significant using Benjamini-Hochberg procedure with a false discovery rate of Q = 
0.1. np indicates non parametric Mann-Whitney test 
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Figure 1 Correlations between actigraphy-derived sleep parameters and Functional 
Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) score (panels A to E), and 
correlation between the Insomnia Severity Index score and FACIT-F (panel F). A lower 
FACIT-F score indicates higher fatigue severity. 
  
22 
 
Supplemental Table 1 : Correlation between sleep and rest-activity cycle parameters, Functional Assessment of 
Chronic Illness Therapy-Fatigue Scale (FACIT-F) 
  FACIT-F     
Pearson Sig. N 
TST 0,042 0,696 87 
WASO -,275 0,010 87 
SE ,258 b 0,016 87 
SOLnp -,305 b 0,004 87 
FI -0,164 0,130 87 
Index activity wake % 0,040 0,712 87 
Index activity sleep % -,385 a 0,000 87 
Mean wake Actigraphy 0,092 0,396 87 
Mean Sleep Actigraphynp -,392 a 0,001 87 
Amplitude (RA)np ,313 a 0,003 87 
Peak time -,323 a 0,002 87 
IS (stability) 0,168 0,120 87 
IV (variability) 0,015 0,889 87 
Bed time -,263 b 0,014 87 
Wake-up time -,282 a 0,008 87 
a Correlation is significant at 0,01 level (bilateral).    
b Correlation is significant at 0,05 level (bilateral).    
np indicate non parametric spearman correlation test    
 
 
 
 
 
 
 
 
Supplemental Table 2: Correlation between sleep estimated parameters and Insomnia Severity Index (ISI). 
  
ISI     
Pearson Sig. N 
FACIT-F -,560a 0,000 66 
TST -0,076 0,546 66 
WASO 0,242 0,051 66 
SE -,336 a 0,006 66 
SOLnp ,303 a 0,013 66 
FI 0,064 0,608 66 
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a Correlation is significant at 0,01 level (bilateral).    
b Correlation is significant at 0,05 level (bilateral).    
np indicate non parametric spearman correlation test    
 
 
 
